Eton Pharmaceuticals, Inc.
ETON
Updated: 22/09/2026, 09:33:08
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
No summaries found.
- Share price
- $55.31
- Market cap
- $1.52B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Sean E. Brynjelsen
- Employees
- 44
- IPO date
- 14/11/2018
- Beta
- 0.9
- Last dividend
- $0.00
- Day range
- $55.22 – $56.67
- 52-week range
- $14.27 – $66.37
- 1-day performance
- -0.34%
- 1-year performance
- 287.60%
- Current drawdown (1Y)
- -16.66%
- CIK
- 0001710340
- CUSIP
- 29772L108
- ISIN
- US29772L1089
- Created
- 07/12/2025, 03:51:13
- Last update
- 22/09/2026, 09:33:08
Track Eton Pharmaceuticals, Inc. with an AI analyst
See which prediction-market events move ETON, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Eton Pharmaceuticals Inc (ETON) Shares Fall 4.3% -- What GF Score of 70 Tells Investors
GuruFocus • STOCK • 29/05/2026, 22:22:00
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
GlobeNewsWire • STOCK • 19/05/2026, 18:30:00
Eton Pharmaceuticals (NASDAQ: ETON) Stock Analysis: H.C. Wainwright Boosts Price Target Amid Strong Performance
Market Data • Market Data • 15/05/2026, 16:04:43
Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 14/05/2026, 23:00:45
Eton Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat • STOCK • 14/05/2026, 22:05:48
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates
Zacks Investment Research • STOCK • 14/05/2026, 20:31:06
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewsWire • STOCK • 12/05/2026, 18:30:00
Eton Pharmaceuticals (ETON) Surges 19.8%: Is This an Indication of Further Gains?
Zacks Investment Research • STOCK • 04/05/2026, 11:55:42
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
GlobeNewsWire • STOCK • 01/05/2026, 08:50:00
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
GlobeNewsWire • STOCK • 27/04/2026, 08:50:00
Eton Pharmaceuticals Announces CFO Succession Plan
GlobeNewsWire • STOCK • 16/04/2026, 08:50:00
Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock?
Zacks Investment Research • STOCK • 24/03/2026, 11:16:09